Start-up focusses on human-derived antibody drugs

Human antibodies

Biotechnology company Infinimmune has closed a $12 million seed round to focus on human-derived antibody drugs.

The seed funding was led by Playground Global, with participation from Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier.

“The industry has proven the value of antibody-based drugs, but the limited number of both drugs and targets demonstrates a need for new approaches to discovery,” said Wyatt McDonnell, CEO and Co-founder of Infinimmune. 

“We aim to take full advantage of truly human antibodies, identifying better and safer drug candidates more efficiently. We’re thrilled that this world-class group of investors shares our vision, and we are excited to expand our team, develop our R&D capabilities, and scale our operations.”

Infinimmune founders Wyatt McDonnell, Katie Pfeiffer, Mike Gibbons, Lance Hepler, and David Jaffe have led development teams at 10x Genomics, Pacific Biosciences, and the Broad Institute.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free